HOME >> BIOLOGY >> NEWS
Two-pronged attack targeting EGF receptor hinders cancer cell growth

Hitting the epidermal growth factor receptor (EGFR) both high and low with a combination of drugs for targeted cancer therapy curbs cancer cell growth more effectively than using the drugs each by themselves, researchers from the University of Wisconsin-Madison reported in the August 1 issue of the journal Cancer Research.

EGFR drives unregulated growth in many types of cancer, and the new molecular cancer drugs, cetuximab (Erbitux, ImClone), and gefitinib (Iressa, AstraZeneca) have recently gained FDA approval as therapeutics targeted at the EGFR to inhibit cancer cell proliferation. A third EGFR inhibiting drug, and erlotinib (Tarceva, Genentech), may have FDA approval within a year.

The Wisconsin study examined the combined effect of Erbitux with either Iressa or Tarceva to control growth of head and neck, prostate, and lung cancer cell lines grown in culture, and lung cancer tumors developing in animals.

Tandem application of either Erbitux and Iressa, or Erbitux and Tarceva, proved synergistically more effective than single drug treaent at several levels.

"The combination of Erbitux with either Iressa or Tarceva inhibited cancer cell growth both in cell culture and in live animals more effectively than any of the drugs alone," said the study's senior author, Paul Harari, M.D., associate professor of human oncology, University of Wisconsin Medical School and Comprehensive Cancer Center.

"The impact of these drugs in combination exceeded the effect each had on controlling the growth, cellular signaling, and tumor development when administered alone," added Shyhmin Huang, Ph.D., a senior scientist in Harari's laboratory and lead author on the publication.

The anti-EGFR drugs are of two types:

  • The monoclonal antibody Erbitux hits the EGFR high, binding to a specific site on the receptor outside the cell membrane. Erbitux blocks the receptor from responding to extracellular signals that tu
    '"/>


Contact: Russell Vanderboom, PhD
vanderboom@aacr.org
215-440-9300
American Association for Cancer Research
1-Aug-2004


Page: 1 2 3

Related biology news :

1. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
2. Smart gene therapy protects against damage from heart attack
3. Reading hexametric rhyme supports cardiac synchronization, especially after a heart attack
4. New standard to help diagnose heart attacks
5. Variation of gene associated with decreased risk of heart attack and stroke
6. Dampened hopes for transplanting bone marrow stem cells in heart attacks
7. Protein may help prevent autoimmune attacks
8. Biosensor-regulated gene therapy reduces heart attack damage in mice
9. Lion attacks on livestock in Africa are significant but manageable
10. New approach limits damage after heart attack and improves survival, say Scripps Research scientists
11. Stem-cell therapy could have benefits and risks for heart-attack PTs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
(Date:12/15/2016)... 2016 Advancements in biometrics will ... and wellbeing (HWW), and security of vehicles ... passenger vehicles begin to feature fingerprint recognition, ... beat monitoring, brain wave monitoring, stress detection, ... pulse detection. These will be driven by ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... ... January 24, 2017 , ... Nor-Tech’s leading-edge demo cluster is ... bootable Intel KNL. , Currently Cal Tech researchers are testing their code ... demo cluster is a no-cost, no-strings opportunity for current and prospective clients to ...
(Date:1/24/2017)... ... 23, 2017 , ... Edward Buckler, Ph.D., a research geneticist ... Academy of Sciences Prize in Food and Agriculture Sciences. He is being honored ... Academy of Sciences (NAS) Prize in Food and Agriculture Sciences was established in ...
(Date:1/24/2017)... January 23, 2017 According to ... by Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, ... (Pharmaceutical & Biotech Companies, CRO) - Global Forecast to ... Humanized Mouse Model Market for the forecast period of ... USD 116.0 Million by 2021 from USD 73.3 Million ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
Breaking Biology Technology:
Cached News: